Cooper Co (CP60) AI Stock Analysis

Cooper Co

(XETRA:CP60)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Solid Revenue GrowthSustained revenue expansion indicates continued demand across Cooper’s vision-care and women’s-health businesses. A growing top line provides a durable base for operating leverage, supports investment in product development and commercial coverage, and can strengthen the company’s position over multiple quarters.

Negative Factors

Weak Cash ConversionThe sharp deterioration in operating and free cash flow makes reported earnings less dependable as a measure of internally generated funding. If cash conversion remains weak, Cooper may have less capacity for innovation, acquisitions and capital returns, while working-capital or spending pressures could persist.

Cooper Co (CP60) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 11.66B
Dividend Yield: ―
Average Volume (3M): 196
Price to Earnings (P/E): 20.9
Beta (1Y): 0.65
Revenue Growth: -1.52%
EPS Growth: 36.06%
Country: Germany
Employees: 15,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact...

Cooper Co Earnings Call Summary

Earnings Call Date:Sep 08, 2026(Q3-2026)|% Change Since:-5.75%|Next Earnings Date:Dec 02, 2026

Earnings Call SentimentPositive

The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.

Positive Updates

Earnings Beat Expectations

Non-GAAP EPS increased 4% year-over-year to $1.15, including approximately $0.03 from tariff refunds. This was the company's 11th consecutive quarter exceeding consensus earnings expectations.

Negative Updates

CooperVision Revenue Flat in Q3

CooperVision revenue was $717 million, essentially flat year-over-year. Results in the Americas reflected proactive U.S. channel inventory reductions.

Company Guidance

For Q4, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%; CooperVision revenue of $692 million to $706 million, down 2% to flat organically; CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%; interest expense of roughly $25 million; a non-GAAP effective tax rate of roughly 16%; non-GAAP EPS of $1.05 to $1.09; and around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million. MiSight growth is expected to be in the low teens in Q4, resulting in roughly 20% growth for this full year, while the company expects $2.2 billion of cumulative free cash flow in fiscal '26 to 2028 and, in fiscal 2027, its scheduled GILTI increase of roughly 2% to increase the non-GAAP effective tax rate from roughly 15.5% this year to roughly 17.5% in fiscal 2027.

Cooper Co Risk Analysis

Cooper Co disclosed 41 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Our business faces significant risks. These risks include those referenced below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. Our business, financial condition and results of operations could be materially adversely affected by any of these risks, and the trading prices of our common stock could decline by virtue of these risks. These risks should be read in conjunction with the other information in this report.Q2, 2026

Cooper Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:CP60 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	71Outperform	$5.17B	31.34	9.65%	―	9.34%	33.77%
BLCO	65Neutral	$7.15B	-64.61	-1.73%	―	8.88%	63.73%
TFX	55Neutral	$5.92B	-6.04	-31.83%	0.97%	-14.49%	-644.98%
STAA	52Neutral	$1.23B	311.75	1.08%	―	51.30%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	45Neutral	$11.90B	-17.55	-11.62%	0.17%	5.33%	-164.67%

* Healthcare Sector Average

Performance Comparison

DE:CP60 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CP60	Cooper Companies	54.56	-4.94	-8.30%
BAX	Baxter International Inc	24.22	6.30	35.19%
MMSI	Merit Medical	84.31	-2.80	-3.21%
STAA	Staar Surgical Company	24.94	-0.31	-1.23%
TFX	Teleflex	140.67	17.29	14.02%
BLCO	Bausch + Lomb Corporation	20.01	4.28	27.21%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cooper Co AI Stock Analysis